



IFW

**TRANSMITTAL  
FORM***(To be used for all correspondence  
after initial filing)*

Application Number	10/728,738
Filing Date	December 4, 2003
First Named Inventor	Andreas H. Sarris
Art Unit	1615
Examiner Name	
Attorney Docket No.	480208.401C2

**ENCLOSURES (check all that apply)**

- |   |
|---|
| <input type="checkbox"/> Fee Transmittal Form                                       |
| <input type="checkbox"/> Fee Attached   |
| <input type="checkbox"/> Amendment/Response   |
| <input type="checkbox"/> After Final  |
| <input type="checkbox"/> Affidavits/declaration(s)                                  |
| <input type="checkbox"/> Extension of Time Request                                  |
| <input type="checkbox"/> Express Abandonment Request                                |
| <input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO-1449 |
| <input checked="" type="checkbox"/> Cited References                                |
| <input type="checkbox"/> Certified Copy of Priority Document(s)                     |
| <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53     |
| <input type="checkbox"/> Response to Missing Parts/Incomplete Application           |

- |  |
|--|
| <input type="checkbox"/> Drawing(s)  |
| <input type="checkbox"/> Request for Corrected Filing Receipt                            |
| <input type="checkbox"/> Licensing-related Papers  |
| <input type="checkbox"/> Petition  |
| <input type="checkbox"/> Petition to Convert to a Provisional Application                |
| <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address |
| <input type="checkbox"/> Declaration   |
| <input type="checkbox"/> Statement under 37 CFR 3.73(b)                                  |
| <input type="checkbox"/> Terminal Disclaimer   |
| <input type="checkbox"/> Request for Refund  |

- |   |
|---|
| <input type="checkbox"/> CD(s), Number of CD(s) _____   |
| <input type="checkbox"/> After Allowance Communication to Technology Center (TC)                              |
| <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences                           |
| <input type="checkbox"/> Appeal Communication to TC ( <i>Appeal Notice, Brief, Reply Brief</i> )              |
| <input type="checkbox"/> Proprietary Information  |
| <input type="checkbox"/> Status Letter  |
| <input checked="" type="checkbox"/> Return Receipt Postcard   |
| <input type="checkbox"/> Additional Enclosure(s) ( <i>please identify below</i> ):<br>_____<br>_____<br>_____ |

Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Individual Name	Carol D. Laherty, Ph.D.	Customer Number <b>00500</b>
Signature		
Date	September 2, 2004	

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Jason Añover	
Signature		Date: September 2, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 510643



PATENT

Hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

September 4, 2004  
Date

Jason Añover

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Andreas H. Sarris et al.  
Application No. : 10/728,738  
Filed : December 4, 2003  
For : COMPOSITIONS AND METHODS FOR TREATING  
LYMPHOMA

Art Unit : 1615  
Docket No. : 480208.401C2  
Date : September 2, 2004

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449. Applicants note that since the application filing date is after June 30, 2003, copies of the cited U.S. patents and published patent applications are not required and accordingly have not been provided. Copies of all other cited references are enclosed. As to any reference cited, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark


Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

  
Carol D. Laherty, Ph.D.  
Registration No. 44,614

Enclosures:

Postcard  
Form PTO-1449  
Cited References (21)

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

510645

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

480208.401C2

APPLICATION NO.

10/728,738

INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)

APPLICANTS

Andreas H. Sarris et al.

FILING DATE

December 4, 2003

GROUP ART UNIT

1615

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,186,183	01/29/80	Steck et al.	424	38	
	AB	4,217,344	08/12/80	Vanlerberghe et al.	424	60	
	AC	4,235,871	11/25/80	Papahadjopoulos et al.	424	19	
	AD	4,261,975	04/14/81	Fullerton et al.	424	89	
	AE	4,485,054	11/27/84	Mezei et al.	264	4.6	
	AF	4,501,728	02/26/85	Geho et al.	424	38	
	AG	4,603,044	07/29/86	Geho et al.	424	9	
	AH	4,737,323	04/12/88	Martin et al.	264	4.3	
	AI	4,774,085	09/27/88	Fidler	424	85.5	
	AJ	4,837,028	06/06/89	Allen	424	450	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK	WO 91/17424	11/14/91	WIPO		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AL	Bloomfield, V., "Quasi-Elastic Light Scattering Application in Biochemistry and Biology," <i>Ann. Rev. Biophys. Bioeng.</i> 10:421-450, 1981.
	AM	Deamer, D. et al., "Larger Volume Liposomes by an Ether Vaporization Method," <i>Biochim. et Biophys. Acta</i> 443:629-634, 1976.
	AN	Dumontet, C. et al., "Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell Death," <i>J. Clin. Oncol.</i> 17(3):1061-1070, March 1999.
	AO	Fraley, R. et al., "Entrapment of a Bacterial Plasmid in Phospholipid Vesicles: Potential for Gene Transfer," <i>Proc. Natl. Acad. Sci. USA</i> 76(7):3348-3352, July 1979.
	AP	Gruner, S., <i>Liposomes - from Biophysics to Therapeutics</i> , Marcel Dekker, Inc., New York, Ch. 1, "Materials Properties of Liposomal Bilayers," pp. 1-38.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 480208.401C2	APPLICATION NO. 10/728,738
INFORMATION DISCLOSURE STATEMENT (Use separate sheets if necessary)		APPLICANTS Andreas H. Sarris et al.	
		FILING DATE December 4, 2003	GROUP ART UNIT 1615

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA	4,885,172	12/05/89	Bally et al.	424	417	
	BB	4,946,787	08/07/90	Eppstein et al.	435	240.2	
	BC	4,952,408	08/28/90	Rahman	424	450	
	BD	4,957,773	09/18/90	Spencer et al.	427	39	
	BE	5,059,421	10/22/91	Loughrey et al.	424	417	
	BF	5,077,056	12/31/91	Bally et al.	424	450	
	BG	5,165,922	11/24/92	Hellstrom et al.	424	85.8	
	BH	5,171,578	12/15/92	Bally et al.	424	450	
	BI	5,543,152	08/06/96	Webb et al.	424	450	
	BJ	5,567,592	10/22/96	Benet et al.	435	7.21	

## FOREIGN PATENT DOCUMENTS


		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BK					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BL	Heath, T., "Covalent Attachment of Proteins to Liposomes," <i>Methods in Enzymology</i> 149:111-119, 1987.
	BM	Hope, M. et al., "Production of Large Unilamellar Vesicles by a Rapid Extrusion Procedure. Characterization of Size Distribution, Trapped Volume and Ability to Maintain a Membrane Potential," <i>Biochim. et Biophys. Acta</i> 812:55-65, 1985.
	BN	Hope, M. et al., "Generation of Multilamellar and Unilamellar Phospholipid Vesicles," <i>Chemistry and Physics of Lipids</i> 40:89-107, 1986.
	BO	Hudson, W. et al., "Xenotransplantation of Human Lymphoid Malignancies is Optimized in Mice with Multiple Immunologic Defects," <i>Leukemia</i> 12:2029-2033, 1998.
	BP	Kluin-Nelemans, H. et al., "A New Non-Hodgkin's B-Cell Line (DoHH2) with a Chromosomal Translocation t(14;18) (q32;q21)," <i>Leukemia</i> 5(3):221-224, March 1991.

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 480208.401C2	APPLICATION NO. 10/728,738	
		INFORMATION DISCLOSURE STATEMENT (Use extra sheets if necessary)	APPLICANTS Andreas H. Sarris et al.		
			FILING DATE December 4, 2003	GROUP ART UNIT 1615	

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA	5,595,756	01/21/97	Bally et al.	424	450	
	CB	5,714,163	02/03/98	Forssen et al.	424	450	
	CC	5,736,155	04/07/98	Bally et al.	424	450	
	CD	5,741,516	04/21/98	Webb et al.	424	450	
	CE	5,814,335	09/29/98	Webb et al.	424	450	
	CF	5,820,873	10/13/98	Choi et al.	424	283.1	
	CG	5,837,282	11/17/98	Fenske et al.	424	450	
	CH	5,885,613	03/23/99	Holland et al.	424	450	
	CI	6,320,017	11/20/01	Ansell	528	310	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	CJ					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	CK	King, R.E., <i>Remington's Pharmaceutical Sciences</i> , 17 <sup>th</sup> Ed., Mack Publishing Co., Philadelphia, PA, 1985, Part 8, "Pharmaceutical Preparations and Their Manufacture," pp. 1409-1677.
	CL	Leonetti, J-P. et al., "Antibody-Targeted Liposomes Containing Oligodeoxyribonucleotides Complementary to Viral RNA Selectively Inhibit Viral Replication," <i>Proc. Natl. Acad. Sci. USA</i> 87:2448-2451, April 1990.
	CM	Mayer, L. et al., "Vesicles of Variable Sizes Produced by a Rapid Extrusion Procedure," <i>Biochim. et Biophys. Acta</i> 858:161-168, 1986.
	CN	Merck Index, 11 <sup>th</sup> ed. 1989, Entry nos. 9887, 9891, & 9893.
	CO	Renneisen, K. et al., "Inhibition of Expression of Human Immunodeficiency Virus-1 in <i>Vitro</i> by Antibody-Targeted Liposomes Containing Antisense RNA to the <i>env</i> Region," <i>J. Biol. Chem.</i> 265(27):16337-16342, September 1990.

EXAMINER	DATE CONSIDERED
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).	

FORM PTO-1449 (REV. 7-80)	SEP 07 2004 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 480208.401C2	APPLICATION NO. 10/728,738
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Andreas H. Sarris et al.	
		FILING DATE December 4, 2003	GROUP ART UNIT 1615

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DA	08/316,394		Ansell			09/30/94
	DB	08/316,407		Holland et al.			09/30/94
	DC	08/996,783		Ansell			12/23/97
	DD						
	DE						
	DF						
	DG						
	DH						
	DI						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	DJ					
	DK					
	DL					
	DM					
	DN					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DO	Szoka F., "Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes)," <i>Ann. Rev. Biophys. Bioeng.</i> 9:467-508, 1980.
DP	Williams, K. et al., "Low Density Lipoprotein Receptor-Independent Hepatic Uptake of a Synthetic, Cholesterol-Scavenging Lipoprotein: Implications for the Treatment of Receptor-Deficient Atherosclerosis," <i>Proc. Natl. Acad. Sci. USA</i> 85:242-246, January 1988.
DQ	

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).